BlackRock Fund Advisors - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Fund Advisors ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q4 2016$4,000
+100.0%
1,621
+50.0%
0.00%
Q3 2016$2,000
-33.3%
1,081
+15.4%
0.00%
Q2 2016$3,000
-90.0%
937
-91.1%
0.00%
Q1 2016$30,000
-38.8%
10,518
-7.0%
0.00%
Q4 2015$49,000
-40.2%
11,304
+5.4%
0.00%
Q3 2015$82,000
-26.1%
10,726
+7.9%
0.00%
Q2 2015$111,0009,9430.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2015
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,675,889$6,797,0005.97%
PERKINS CAPITAL MANAGEMENT INC 449,950$1,143,0000.89%
Diametric Capital, LP 116,754$297,0000.23%
Granahan Investment Management 924,300$2,348,0000.17%
Requisite Energy Fund I LP 100,000$254,0000.10%
Requisite Capital Management, LLC 100,000$254,0000.10%
B. Riley Wealth Advisors, Inc. 250,000$635,0000.09%
Kalos Management, Inc. 74,420$179,0000.09%
Crow Point Partners, LLC 65,475$164,0000.03%
ARDSLEY ADVISORY PARTNERS LP 35,000$89,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders